Drug Profile
Research programme: tumour reversion therapeutics - Cerep
Alternative Names: CER 233790Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Cerep
- Class
- Mechanism of Action Cell cycle protein inhibitors; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in France (PO)
- 10 May 2007 Preclinical trials in Cancer in France (PO)